Source-grounded facts extracted from GLOBUS MEDICAL INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
GLOBUS MEDICAL INC shareholders approved Approval, on a non-binding, advisory basis, of the 2025 compensation of the Company’s named executive officers.
“The Company’s stockholders approved, on a non-binding, advisory basis the 2025 compensation of the Company’s named executive officers, as described in the Proxy Statement.”
GLOBUS MEDICAL INC shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026 at the 2026-12-31 meeting.
“The Company’s stockholders approved the ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.”
GLOBUS MEDICAL INC shareholders approved Approval of 2021 Equity Incentive Plan Amendment.
“The Company’s stockholders approved the 2021 Equity Incentive Plan Amendment.”
GLOBUS MEDICAL INC shareholders approved Election of two Class II directors to serve until the 2029 Annual Meeting of Stockholders.
“Each of the director nominees listed below were elected by the Company’s stockholders at the Annual Meeting to serve a three-year term on the Board.”
GLOBUS MEDICAL INC reported full-year 2026 results: revenue $3.18 billion to $3.22 billion, EPS $4.70 to $4.80. Guidance raised.
“The Company reaffirms its guidance for full-year 2026 revenue to be in the range of $3.18 billion to $3.22 billion and updates its guidance for non-GAAP fully diluted EPS to be in the range of $4.70 to $4.80 from the previous range of $4.40 to $4.50.”
GLOBUS MEDICAL INC reported the first quarter ended March 31, 2026 results: revenue $759.9 million, net income $124.3 million, EPS $0.90.
“Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal technology company, today announced its financial results for the first quarter ended March 31, 2026. First Quarter 2026: • Worldwide net sales were $759.9 million, an increase of 27.0%, or an increase of 25.5% on a constant currency basis. • Base business, excluding Nevro, net sales were $677.2 million, an increase of 13.2%, or an increase of 11.2% on a constant currency basis. • GAAP net income for the quarter was $124.3 million. • GAAP diluted earnings per share (“EPS”) was $0.90, an increase of 66.6%.”
GLOBUS MEDICAL INC completed an acquisition involving Nevro Corp. for $5.85 per Nevro Share in cash (closed 2025-04-03).
“or Nevro or by any direct or indirect wholly owned subsidiary of Globus, Merger Sub or Nevro was canceled and extinguished and automatically converted into the right to receive $5.85 per Nevro Share in cash (the “Merger Consideration”), without interest and subject to any applicable withholding taxes. In addition, effective as of immediately prior to the”
GLOBUS MEDICAL INC reported three-month period ended March 31, 2024 results: revenue $606.7 million, net income $7.1 million net loss, EPS ($0.05).
“Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended March 3 1 , 202 4 . · Worldwide net sales were $ 606.7 million , an increase of 119 . 3 % , or 119.8% on a constant currency basis · GAAP net loss for the quarter was $ 7. 1 million · GAAP d iluted e arnings p er share (“ EPS ”) was ( $0. 0”
GLOBUS MEDICAL INC reported the fiscal year ended December 31, 2023 results: revenue $ 1,568.5 million, net income $ 122.9 million, EPS $1.07. Guidance reaffirmed.
“EPS ”) was $0. 11 and non-GAAP diluted EPS was $0. 60 · Non-GAAP adjusted EBITDA was $ 1 70.0 million, or 27. 6 % of net sales Full Year 20 2 3 : · Worldwide net sales were $ 1,568.5 million , an increase of 53.3% on an actual and constant currency basis · GAAP n et income for the year was $ 122.9 million · GAAP d iluted EPS was $ 1.07 and n on-GAAP diluted EPS was $”
GLOBUS MEDICAL INC reported the fourth quarter ended December 31, 2023 results: revenue $ 616.5 million, net income $ 15.0 million, EPS $0.11.
“Worldwide net sales for the fourth quarter were $ 616.5 million”
Keith Pfeil changed role as Chief Operating Officer and Chief Financial Officer at GLOBUS MEDICAL INC.
“On February 5, 2024, Globus Medical, Inc. (the “Company”) issued a news release announcing the promotion of Keith Pfeil to Chief Operating Officer and Chief Financial Officer, effective as of February 1, 2024.”
GLOBUS MEDICAL INC updated its the three-month period and fiscal year ended December 31, 2023 guidance (initiated).
“On January 10, 2024, we issued a press release reporting our preliminary unaudited net sales results for the three-month period and fiscal year ended December 31, 2023. The press release also included preliminary guidance for certain financial measures for the 2024 fiscal year.”
GLOBUS MEDICAL INC reported full year fiscal 2023 results: revenue $1.55 billion, EPS $2.30. Guidance raised.
“The Company today increased its full year fiscal 2023 revenue guidance to $1.55 billion, up from $1.125 billion, and reaffirmed non-GAAP fully diluted earnings per share guidance of $2.30.”
GLOBUS MEDICAL INC reported the quarter ended September 30, 2023 results: revenue $383.6 million, net income $1.0 million, EPS $0.01.
“merger with NuVasive, Inc. was completed on September 1, 2023 and results presented within include NuVasive, Inc. results from that closing date . · Worldwide net sales were $ 383.6 million , an increase of 5 1.0 % . · GAAP net income for the quarter was $ 1.0 million · GAAP d iluted earnings per share (“ EPS ”) was $0. 0 1 and non-GAAP diluted EPS was $0. 57 ·”
GLOBUS MEDICAL INC entered into Credit Agreement with U.S. Bank National Association, as the administrative agent valued at $400 million (effective 2023-09-27).
“On September 27, 2023, Globus Medical, Inc. (the “Company”), together with Globus Medical North America, Inc., the Company’s wholly-owned subsidiary (with the Company, the “Borrowers”) entered into an unsecured credit agreement (the “Credit Agreement”) with U.S. Bank National Association, as the administrative agent (the “Agent”), Citizens Bank, N.A., as syndication agent, Royal Bank of Canada, as the documentation agent, U.S. Bank National Association and Citizens Bank, N.A., as joint lead arrangers and joint book runners, and the other lenders referred to therein.”
GLOBUS MEDICAL INC completed an acquisition involving NuVasive, Inc. for 0.75 shares of Globus Class A Common Stock (closed 2023-09-01).
“owned subsidiary of Globus. At the consummation of the Merger, each issued and outstanding share of common stock of NuVasive, $0.001 par value per share, was converted into 0.75 fully paid and non-assessable shares of Globus Class A Common Stock, and the right to receive cash in lieu of fractional shares. The issuance of Globus Class A Common Stock in”
GLOBUS MEDICAL INC amended convertible notes of $450.0 million with Wilmington Trust, National Association at 0.375% per annum maturing March 15, 2025.
“2, 2020 (the “Base Indenture” and, together with that certain First Supplemental Indenture, the “Indenture”), by and between NuVasive and the Trustee, relating to NuVasive’s $450.0 million in aggregate principal amount of 0.375% Convertible Senior Notes due 2025 (the “Notes”). As a result of the Merger, and pursuant to the First Supplemental Indenture, the Notes”
GLOBUS MEDICAL INC entered into First Supplemental Indenture with Wilmington Trust, National Association valued at $450.0 million (effective 2023-09-01).
“on September 1, 2023, Globus Medical, Inc., a Delaware corporation (“Globus”), NuVasive, Inc., a Delaware corporation (“NuVasive”), and Wilmington Trust, National Association, as trustee (the “Trustee”) entered into that certain First Supplemental Indenture (the “First Supplemental Indenture”) to the Indenture, dated as of March 2, 2020 (the “Base Indenture” and, together with that certain First Supplemental Indenture, the “Indenture”), by and between NuVasive and the Trustee, relating to NuVasive’s $450.0 million in aggregate principal amount of 0.375% Convertible Senior Notes due 2025 (the “Notes”).”
Daniel J. Wolterman was appointed as Director at GLOBUS MEDICAL INC.
“on September 1, 2023, the board of directors of Globus (the “Globus Board”) elected and designated Leslie V. Norwalk, John A. DeFord, and Daniel J. Wolterman (collectively, the “New Directors”), who were previously members of the board of directors of NuVasive, to serve on the Globus Board effective immediately after the consummation of the Merger.”
John A. DeFord was appointed as Director at GLOBUS MEDICAL INC.
“on September 1, 2023, the board of directors of Globus (the “Globus Board”) elected and designated Leslie V. Norwalk, John A. DeFord, and Daniel J. Wolterman (collectively, the “New Directors”), who were previously members of the board of directors of NuVasive, to serve on the Globus Board effective immediately after the consummation of the Merger.”
Leslie V. Norwalk was appointed as Director at GLOBUS MEDICAL INC.
“on September 1, 2023, the board of directors of Globus (the “Globus Board”) elected and designated Leslie V. Norwalk, John A. DeFord, and Daniel J. Wolterman (collectively, the “New Directors”), who were previously members of the board of directors of NuVasive, to serve on the Globus Board effective immediately after the consummation of the Merger.”
GLOBUS MEDICAL INC updated its three-month period ended June 30, 2023 guidance (raised).
“On August 3, 2023, we issued a press release reporting, among other things, our sales and operating results for the three-month period ended June 30, 2023.”
GLOBUS MEDICAL INC shareholders approved Non-binding advisory vote to approve the compensation of the Company’s named executive officers at the 2023-06-07 meeting.
“Proposal 4 A non-binding advisory vote to approve the compensation of the Company’s named executive officers, as described in the Company’s definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission. This proposal was approved. For Against Abstain Broker Non-Vote 278,760,964 4,855,821 81,727 5,937,823”
GLOBUS MEDICAL INC shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023 at the 2023-06-07 meeting.
“Proposal 3 Ratification of the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2023. This proposal was approved. For Against Abstain Broker Non-Vote 289,461,330 144,307 30,698 0”
GLOBUS MEDICAL INC shareholders approved Approval of the Amendment to the 2021 Equity Incentive Plan at the 2023-06-07 meeting.
“Proposal 2 Approval of the Amendment to the 2021 Equity Incentive Plan: For Against Abstain Broker Non-Vote 229,917,089 53,722,734 58,689 5,937,823”
GLOBUS MEDICAL INC shareholders approved Election of Directors at the 2023-06-07 meeting.
“Proposal 1 The individuals listed below were each elected at the Annual Meeting to serve a three-year term on the Company’s Board of Directors. Nominee For Withhold Broker Non-Vote Daniel T. Scavilla 249,448,775 34,249,737 5,937,823 Robert A. Douglas 281,453,058 2,245,454 5,937,823”
GLOBUS MEDICAL INC reported three-month period ended March 31, 2023 results: revenue $276.7 million, net income $49.1 million, EPS $0.48.
“· Worldwide net sales were $276.7 million , an increase of 20.0% , or 21.0% on a constant currency basis · GAAP net income for the quarter was $49.1 million · GAAP d iluted earnings per share (“ EPS ”) was $0.48”
GLOBUS MEDICAL INC shareholders approved Approval of issuance of shares in connection with the Merger at the 2023-04-27 meeting.
“Globus Share Issuance Proposal . To vote to approve the issuance of shares of Globus Class A Common Stock in connection with the Merger (the “Globus Share Issuance Proposal”). Votes For Votes Against Abstentions 287,038,438 210,302 2,666,263”
GLOBUS MEDICAL INC reported Full Year 2022 results: revenue $1,022.8 million, net income $190.2 million, EPS $1.85.
“Full Year 20 2 2 : · Worldwide net sales were $ 1,022.8 million , an increase of 6.8 % , or 8.2% on a constant currency basis · GAAP n et income for the year was $ 1 90.2 million · GAAP d iluted EPS was $ 1. 85 and n on-GAAP diluted EPS was $ 2.0 6 · Non-GAAP adjusted EBITDA was $ 33 9.2 million, or 3 3.2 % of net sales”
GLOBUS MEDICAL INC entered into Agreement and Plan of Merger with NuVasive, Inc. (effective 2023-02-08).
“On February 8, 2023, NuVasive, Inc., a Delaware corporation (“NuVasive”), entered into an Agreement and Plan of Merger (the “Merger Agreement”) with Globus Medical, Inc., a Delaware corporation (“Globus Medical”) and Zebra Merger Sub, Inc., a Delaware corporation and a wholly owned subsidiary of Globus Medical (“Merger Sub”).”
GLOBUS MEDICAL INC reported preliminary financial results for the year ended December 31, 2022.
“On February 9, 2023, Globus Medical, Inc. (“Globus Medical” or the “Company”) issued the Joint Press Release (as defined in Item 7.01 below) which contained certain preliminary financial results for the year ended December 31, 2022.”
GLOBUS MEDICAL INC reported quarter ended September 30, 2022 results: revenue $254.1 million, net income $47.4 million, EPS $0.47. Guidance reaffirmed.
“Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced its financial results for the quarter ended September 30, 2022 . · Worldwide net sales were $254.1 million , an increase of 10.6% , or 12.6% on a constant currency basis · GAAP net income for the quarter was $47.4 million · GAAP d iluted earnings per share (“ EPS ”) was $0.47 and”
Daniel T. Scavilla was appointed as Director at GLOBUS MEDICAL INC.
“On April 21, 2022, the Board appointed Mr. Scavilla to serve as a member of the Board and as a member of the Nominating and Corporate Governance Committee with a term expiring at the Company’s annual meeting in 2023 to fill the vacancy created by the resignation of Mr. Demski.”
Daniel T. Scavilla was appointed as President and Chief Executive Officer at GLOBUS MEDICAL INC.
“On April 21, 2022, the Board of Directors of the Company approved the appointment of Daniel T. Scavilla as President and Chief Executive Officer, effective April 21, 2022.”
David M. Demski resigned as Director at GLOBUS MEDICAL INC.
“On April 20, 2022, David M. Demski notified the Chairman of the Board of Directors (the “Board”) of the Company of his resignation from the Board effective April 20, 2022.”
David M. Demski resigned as President and Chief Executive Officer at GLOBUS MEDICAL INC.
“On April 20, 2022, Mr. Demski also notified the Board of his resignation as President and Chief Executive Officer of the Company, effective April 21, 2022.”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.